Leadman(SZ:300289)2018-04-26 16:00Financial Performance - Total revenue for Q1 2018 was CNY 171,566,362.27, representing a 51.54% increase compared to CNY 113,214,868.77 in the same period last year[8]. - Net profit attributable to shareholders was CNY 18,354,315.84, up 10.56% from CNY 16,601,202.09 year-on-year[8]. - The company reported non-recurring gains of CNY 1,638,438.30 during the reporting period, primarily from government subsidies and asset disposals[9]. - The company achieved operating revenue of 171.57 million yuan, a year-on-year increase of 51.54%[28]. - The net profit attributable to shareholders was 18.35 million yuan, representing a growth of 10.56% compared to the same period last year[28]. - The total profit for the first quarter was CNY 28,679,155.45, compared to CNY 23,215,389.97 in the previous year, which is an increase of approximately 23.5%[51]. - The operating profit for the first quarter was CNY 13,294,662.30, up from CNY 10,537,064.68 in the same period last year, reflecting an increase of about 26.3%[54]. Cash Flow - Net cash flow from operating activities was negative CNY 12,820,152.99, a decline of 216.53% compared to negative CNY 4,050,249.58 in the previous year[8]. - The cash flow from operating activities was -12,820,152.99, worsening from CNY -4,050,249.58 in the same quarter last year[60]. - The company incurred a total operating cost of CNY 24,763,515.29, down from CNY 31,017,416.84 in the previous year, indicating a reduction of about 20.2%[54]. - The company reported a net decrease in cash and cash equivalents of -80,835,568.60 CNY for the period[65]. - Cash outflow from operating activities was 82,005,064.76 CNY, compared to 73,836,334.46 CNY in the previous period, reflecting increased operational costs[63]. - The cash flow from investment activities was -11,233,806.66 CNY, worsening from -1,608,846.00 CNY in the previous period[63]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,720,571,266.64, down 1.90% from CNY 1,753,893,000.69 at the end of the previous year[8]. - Total liabilities decreased to CNY 236,114,079.00 from CNY 292,854,509.19 at the beginning of the year, indicating a reduction of 19.4%[47]. - Shareholders' equity increased to CNY 1,450,064,155.29 from CNY 1,438,770,821.96, showing a growth of 0.9%[47]. - Accounts receivable increased by 20.64%, from RMB 144.14 million at the beginning of the period to RMB 173.89 million at the end of the period[22]. - Inventory rose to CNY 72,136,990.66 from CNY 66,840,985.31, reflecting an increase of 7.0%[44]. Operational Highlights - The proportion of diagnostic reagent sales to total revenue was 88.94% in Q1 2018, slightly down from 89.57% in 2016 and 87.86% in 2017[12]. - The in vitro diagnostic reagent business generated revenue of 149.82 million yuan, up 63.38% year-on-year, accounting for 88.94% of total revenue[28]. - The company is focusing on the research and development of chemiluminescence immunoassay products to enhance its product offerings and meet market demands[12]. - The company expanded its direct sales service system and strengthened cooperation with key hospitals and medical testing institutions[29]. - The top five customers contributed 39.35% of total sales revenue, increasing from 38.33% in the previous year[31]. Risks and Challenges - The company faces risks related to policy changes, market competition, and potential impairment of goodwill from acquisitions[10][11]. - The company is focusing on new product development and market expansion to enhance its competitive edge[33].